BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05358821 (SAGE-718 in Huntington's Disease): BVCT ex-ante prediction vs. reported outcome

On 20 Apr 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 11 Jun 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05358821
Acronym
SURVEYOR
Drug Name
SAGE-718
Drug MoA
NMDAR PAM
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Huntington's Disease
Human Patients
69
Sponsor
Sage Therapeutics
Phase
Phase 2

Prediction of , index 1381

Prospective Prediction
Prediction Index
1381
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
FAILURE (statistically insignificant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
52 days in advance
Readout Data Interpretation
only trends of functional improvement IN HD-CAB thus statistically insignificant.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
Phase
Phase 2
Status
Completed
Enrollment
69
Lead sponsor
Supernus Pharmaceuticals, Inc.
Conditions
Huntington Disease
Interventions
DRUG: SAGE-718; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2022-05-26
Primary completion
2024-02-29
Completion
2024-04-10
Results first posted
2025-05-06
Primary outcomes
  • Difference in Huntington's Disease Cognitive Assessment Battery (HD-CAB) Composite Score Between Participants With HD vs HP at Baseline (Baseline)

NCT05358821 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials